AbbVie is a biopharma company behind Humira’s successors Skyrizi and Rinvoq, plus aesthetics (Botox). It trades on NYSE under the ticker ABBV, in the Pharmaceuticals sector.
Key Facts
| Item | Details |
|---|---|
| Ticker | ABBV |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Headquarters | North Chicago, IL, USA |
Bull Case & Risks
Bull Case
- A fast-growing immunology franchise (Skyrizi/Rinvoq)
- Diversification beyond Humira
- A high dividend yield
Risks
- Humira erosion from biosimilars
- Pipeline and pricing risk
Outlook
AbbVie has navigated the Humira patent cliff with strong successor drugs; the bull case is Skyrizi/Rinvoq growth offsetting legacy declines.
Educational information only, not investment advice. Stocks carry risk including possible loss of principal; past performance does not guarantee future results.